echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Drug terminal sales and circulation cost accounts for 60%

    Drug terminal sales and circulation cost accounts for 60%

    • Last Update: 2013-08-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: 2013-08-07: the issue of drug price reduction in Beijing Business Daily is a major issue related to the progress of medical reform The events related to the price of government purchased drugs have started again and again First, the national development and Reform Commission began to investigate the cost of drug companies Then, the Shanghai bidding office issued the implementation plan of "purchasing with quantity" which was fiercely opposed by domestic drug companies How to adjust the drug price to meet the market rules and promote the smooth progress of medical reform? Chen qiguang, head of the research group on the situation of traditional Chinese medicine in Chinese Academy of Social Sciences, said that the high drug price is not caused by the manufacturers At present, 30% of the terminal price of purchased drugs is the ex factory price, and 60% is generated by the circulation link To suppress commercial bribery in circulation is the most important thing to adjust the drug price After the emergence of some drug commercial bribery scandals, the national development and Reform Commission began to investigate the cost of pharmaceutical enterprises Some insiders said that the national development and Reform Commission wanted to change the traditional regulation of "ceiling price" of basic drugs in the past, try to find a "payment price" close to the actual sales price of the drug market, and avoid unreasonable high pricing "The government's bottom finding should be in line with the overall statistical bottom finding, so that the data obtained is universal and representative Now every enterprise has different production scale, different technology and different production cost We should avoid generalizing this time " Chen qiguang believes that pharmaceutical enterprises have the right of independent production and operation, and their production costs are trade secrets If they do not want to win the market share of government collective procurement, they are not obliged to disclose their actual production costs to the government Even if the government has figured out the cost price, how much profit margin of government purchasing drugs can hospitals accept it is a question worth pondering "Commercial bribery in circulation is a problem that the government pays more attention to, and the profits of production enterprises are not high." While the national development and Reform Commission is in the process of cost finding, the Shanghai Municipal bidding office has issued the implementation plan of "purchasing with quantity" which is fiercely opposed by domestic pharmaceutical enterprises The "Three Focuses" that pharmaceutical enterprises object to include: the theory of low price only; taking too much care of foreign enterprises, but desperately pressing the price of domestic enterprises; regardless of the quality level, all enterprises that have obtained CFDA approval can bid Among them, it is unfair for domestic enterprises to adopt different policies for domestic and foreign enterprises According to the plan, the original research drugs can be included in the volume purchase if the price is reduced by 10%, or even less than 10%, while the generic drugs are the two with the lowest price, even if the price is reduced by 50%, they may not be included in the shortlist At present, most of the original research drugs are produced by foreign capital and joint ventures The R & D of the original new drugs costs US $1 billion in 10 years Such time and money costs are hard for domestic enterprises to bear The low price of generic drugs of domestic enterprises is also impossible to be shortlisted, which arouses fierce opposition from domestic pharmaceutical enterprises "At present, the state has technical preferential measures for the original drugs It is unfair for domestic enterprises that the original research drugs of foreign enterprises can enjoy the independent pricing right, and the original research drugs that have passed the patent period still enjoy the preferential treatment of the original research drugs The state should adjust its procurement policies in this regard, and domestic and foreign enterprises should enjoy national treatment rather than preferential treatment only for foreign enterprises " Chen qiguang told reporters that now that the medical reform has entered the deep water area, the reasonable adjustment of drug prices will be conducive to the adjustment of medical service costs and the return of medicine to the normal medical model  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.